Fintel reports that on January 7, 2025, TD Cowen initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation.
Analyst Price Forecast Suggests 126.12% Upside
As of December 23, 2024, the average one-year price target for CG Oncology is $70.23/share. The forecasts range from a low of $55.55 to a high of $90.30. The average price target represents an increase of 126.12% from its latest reported closing price of $31.06 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for CG Oncology is 11MM, an increase of 1,515.50%. The projected annual non-GAAP EPS is -1.96.
What is the Fund Sentiment?
There are 292 funds or institutions reporting positions in CG Oncology. This is an increase of 29 owner(s) or 11.03% in the last quarter. Average portfolio weight of all funds dedicated to CGON is 0.86%, an increase of 18.66%. Total shares owned by institutions increased in the last three months by 22.75% to 57,275K shares. 
The put/call ratio of CGON is 0.12, indicating a bullish outlook.
What are Other Shareholders Doing?
Decheng Capital holds 5,479K shares representing 8.10% ownership of the company. In its prior filing, the firm reported owning 5,459K shares , representing an increase of 0.37%. The firm decreased its portfolio allocation in CGON by 7.29% over the last quarter.
TCG Crossover Management holds 3,670K shares representing 5.43% ownership of the company. No change in the last quarter.
Braidwell holds 3,171K shares representing 4.69% ownership of the company. In its prior filing, the firm reported owning 3,310K shares , representing a decrease of 4.37%. The firm increased its portfolio allocation in CGON by 3.46% over the last quarter.
Kynam Capital Management holds 1,771K shares representing 2.62% ownership of the company. In its prior filing, the firm reported owning 54K shares , representing an increase of 96.96%. The firm increased its portfolio allocation in CGON by 3,801.29% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,726K shares representing 2.55% ownership of the company. In its prior filing, the firm reported owning 755K shares , representing an increase of 56.25%. The firm increased its portfolio allocation in CGON by 156.59% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
